Company Overview

Pacific Biosciences of California, Inc. (“PacBio”) is a U.S.-based biotechnology company focused on developing and commercializing advanced genomic sequencing technologies for life sciences research and clinical applications. The company operates primarily within the genomics, molecular diagnostics, and biotechnology tools industries. PacBio is best known for its long-read DNA sequencing platforms built on Single Molecule, Real-Time (SMRT) sequencing technology, which is designed to deliver highly accurate genomic data for applications including whole genome sequencing, transcriptomics, epigenetics, oncology research, agricultural genomics, and infectious disease analysis.

The company’s primary revenue drivers include sales of sequencing instruments, consumables, and related services. Key product lines include the Revio System, Sequel IIe System, and associated consumable kits and software platforms. PacBio serves academic institutions, government laboratories, pharmaceutical companies, biotechnology firms, and clinical research organizations globally. The company was founded in 2004 and is headquartered in Menlo Park, California. Over time, PacBio evolved from an emerging sequencing technology developer into a commercial genomics platform provider competing in the high-accuracy long-read sequencing market. Its strategic positioning has been associated with high-fidelity (“HiFi”) sequencing accuracy and the ability to resolve structurally complex regions of the genome that can be difficult for short-read sequencing technologies to analyze effectively.

Business Operations

PacBio generates revenue primarily through its sequencing systems, consumables, and service offerings. The company’s business model depends significantly on recurring consumables sales tied to installed sequencing instruments. Its operations are centered around the commercialization of SMRT sequencing technology and supporting software analytics tools used for genomic interpretation. The company also provides instrument maintenance, technical support, training, and professional services for research customers.

PacBio operates internationally across North America, Europe, and Asia-Pacific through direct commercial operations and distributor relationships. The company maintains research, manufacturing, and commercial infrastructure supporting customers in academic, translational, and pharmaceutical research settings. PacBio has established collaborations with research institutions, clinical laboratories, and genomics-focused organizations to expand adoption of long-read sequencing workflows. Public filings and investor materials identify strategic relationships with genomic research consortia and pharmaceutical partners, although some collaboration terms are not fully disclosed publicly. Data regarding certain private commercial arrangements is inconclusive based on available public sources.

Strategic Position & Investments

PacBio’s strategic direction has focused on expanding adoption of long-read sequencing technologies while increasing throughput and reducing sequencing costs. The company has invested heavily in platform innovation, particularly through the commercialization of the Revio System, which was designed to increase scalability for population-scale genomic studies. PacBio has also pursued software and workflow integration capabilities intended to improve data interpretation and laboratory efficiency.

The company has made targeted acquisitions and investments to strengthen its sequencing ecosystem. Notable transactions include the acquisition of Omniome, a sequencing technology company focused on short-read sequencing technologies, which broadened PacBio’s technology portfolio beyond long-read sequencing. PacBio has also invested in automation, cloud-enabled bioinformatics, and applications in clinical research and multiomics. Strategic emphasis has been placed on oncology, rare disease research, human genetics, and agricultural genomics as long-term growth markets. Public disclosures indicate continued investment in research and development as a core competitive strategy.

Geographic Footprint

PacBio is headquartered in Menlo Park, California, and maintains operations serving customers across North America, Europe, Asia-Pacific, and selected markets in the Middle East and Latin America through distributors and commercial partnerships. The company’s sequencing systems are used by universities, national genome centers, pharmaceutical companies, and biotechnology firms worldwide.

The company has a notable presence in major genomics research markets including the United States, China, Japan, South Korea, Singapore, Germany, and the United Kingdom. International expansion has been supported through regional sales organizations, scientific support teams, and distribution agreements. PacBio’s technologies have been utilized in large-scale genomic initiatives and national sequencing programs, particularly in regions investing heavily in precision medicine and population genomics research.

Leadership & Governance

PacBio is led by an executive team with backgrounds in genomics, biotechnology tools, healthcare, and commercial life sciences operations. The company’s leadership strategy has emphasized technological innovation, expansion of sequencing accessibility, and scaling commercial adoption of high-accuracy long-read sequencing. Governance oversight is provided by its board of directors and executive management team in accordance with public company reporting requirements and Nasdaq governance standards.

Key executives include:

• Christian O. Henry – President and Chief Executive Officer
• Susan Kim – Chief Financial Officer
• Neil Ward – Vice President, Global Marketing
• Kevin Corcoran – Senior Vice President, Operations
• Dr. David Miller – Vice President, Global Clinical and Medical Affairs

PacBio’s leadership communications in public filings and investor presentations have consistently emphasized improving sequencing throughput, supporting scientific discovery, and expanding the use of long-read sequencing in translational and clinical research markets. Information regarding certain executive responsibilities and organizational changes may vary across reporting periods based on the company’s most recent filings and corporate announcements.